Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hatchtech has recruited first subject in its double-blind, randomized, vehicle-controlled Phase 2b clinical study evaluating its novel head lice treatment DeOvo.
Subscribe to our email newsletter
The Phase 2b trial is expected to investigate the efficacy, safety and tolerability of two dose levels of a single application of DeOvo compared to vehicle.
The primary endpoint of the trial is the proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit.
Hatchtech chairman Paul Kelly said DeOvo is a next generation head lice treatment therapy that targets all life cycle stages of the parasite with a single 10 minute application.
"We have previously demonstrated that this agent effectively treats eggs and crawling lice in a small number of infested adults. Now we are assessing the compound in a larger clinical trial including adult and pediatric subjects," Kelly said.